LifeStance Health Group (NASDAQ:LFST) Director Sells $86,597.00 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 12,371 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $7.00, for a total transaction of $86,597.00. Following the completion of the sale, the director directly owned 1,375,989 shares of the company’s stock, valued at approximately $9,631,923. The trade was a 0.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Robert Bessler also recently made the following trade(s):

• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total transaction of $558,206.30.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $6.94 on Friday. The firm has a 50-day moving average price of $5.95 and a two-hundred day moving average price of $5.37. LifeStance Health Group, Inc. has a 12-month low of $3.74 and a 12-month high of $8.30. The company has a market capitalization of $2.70 billion, a P/E ratio of -231.33 and a beta of 1.13. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.02) earnings per share. Analysts anticipate that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds have recently made changes to their positions in LFST. Invesco Ltd. raised its position in shares of LifeStance Health Group by 1.4% during the first quarter. Invesco Ltd. now owns 164,384 shares of the company’s stock worth $1,095,000 after acquiring an additional 2,238 shares during the last quarter. Vident Advisory LLC increased its position in LifeStance Health Group by 12.7% during the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the period. State of Wyoming increased its position in LifeStance Health Group by 3.8% during the 3rd quarter. State of Wyoming now owns 89,927 shares of the company’s stock valued at $495,000 after purchasing an additional 3,298 shares during the period. Legal & General Group Plc raised its holdings in LifeStance Health Group by 2.4% during the 2nd quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock worth $746,000 after purchasing an additional 3,331 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its position in shares of LifeStance Health Group by 19.3% in the 3rd quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company’s stock worth $120,000 after purchasing an additional 3,525 shares during the period. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LFST. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. BTIG Research upped their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Barclays started coverage on shares of LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday. Finally, UBS Group increased their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, LifeStance Health Group has an average rating of “Moderate Buy” and a consensus target price of $8.83.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.